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Abstract
Constitutive nitric oxide synthase (cNOS) may play an important protective role in the intestine, since our previous study
has shown that the degree of bowel injury induced by platelet-activating factor (PAF), a potent inflammatory mediator, is
inversely related to the cNOS content of the intestine. This study aims to examine the composition of the cNOS system in rat
small intestine, and its regulation by PAF. We found that an approximately 120 kDa NOS I (neuronal NOS) is the
predominant NOS in rat intestine, as evidenced by the following: (a) immunoblotting with specific antibodies detected a
NOS I of approximately 120 kDa, but little NOS III; (b) the Ca2-dependent, constitutive NOS (cNOS) activity of the rat
intestine was removed by immunoprecipitation with the anti-NOS I, but not anti-NOS II or anti-NOS III antibodies; (c)
RT^PCR revealed constitutive expression of NOS I in the intestinal tissue, but only a minute amount of NOS III.
Immunofluorescent staining with anti-NOS I located NOS in the Auerbach plexus and nerve fibers in the muscle layer. We
also found that this 120 kDa NOS I is rapidly (within 1 h) down-regulated in response to PAF administration. The protein
level, enzyme activity as well as mRNA of nNOS were all decreased in the intestine. ß 1999 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Nitric oxide (NO), a molecule with extremely ver-
satile function, is produced in the body by the three
members of the nitric oxide synthase (NOS) family:
the constitutive neuronal (type I) nNOS and endo-
thelial (type III) eNOS, and inducible (type II) iNOS
(reviewed in [1]). Previous reports demonstrated that
in the intestine, endogenous NO produced by con-
stitutive NOS (cNOS) plays a pivotal role in main-
taining normal physiological functions, such as reg-
ulation of intestinal motility [2], and protection of
the mucosal barrier [3]. Blockage of physiological
NO production has many adverse e¡ects, such as
loss of epithelial integrity [4], breakdown of the mu-
cosal barrier, microvascular leakage [5], and leuko-
cyte adhesion in postcapillary venules of rat mesen-
tery [6]. Administering NO has been shown to
protect against ischemia/reperfusion injury in the
small intestine [7]. Our previous work also showed
that endogenous NO [8] as well as NO donors [9]
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protect against platelet-activating factor (PAF)-in-
duced intestinal injury.
PAF is a pro-in£ammatory phospholipid mediator
central to endotoxin shock [10] and intestinal injury
[11]. Systemic injection of PAF [12] causes intestinal
necrosis, and lipopolysaccharide (LPS)-induced bow-
el injury can be prevented by pretreatment with PAF
antagonists [11]. Our previous studies [9] have shown
that: (a) in normal intestinal tissue, the predominant
NOS activity comes from cNOS, whereas iNOS,
which is localized in the epithelium, comprises only
5^10% of the total NOS activity; (b) PAF down-
regulates intestinal cNOS activity; and the develop-
ment of intestinal injury after PAF injection inversely
correlates with cNOS activity in the intestine. These
¢ndings call for further characterization of the regu-
lation of NOS isoforms in the small intestine by in-
£ammatory stimuli such as PAF. In the ¢rst part of
the present study we identi¢ed nNOS as the predom-
inant cNOS in the intestine. In the second part, we
examined the e¡ect of PAF on nNOS enzyme activ-
ity, protein levels, and gene expression in the intes-
tine.
2. Materials and methods
2.1. Animal experiment
Male Sprague^Dawley rats (80^120 g) were anes-
thetized with Nembutal and tracheotomized. The
carotid artery and jugular vein were cannulated for
continuous blood pressure monitoring, blood sam-
pling, and drug administration. The animals were
either sham-operated, or injected with 2.5 Wg/kg
(i.v.) of PAF (1-O-hexadecyl-2-acetyl-sn-glycero-3-
phosphocholine, Sigma, St. Louis, MO). One hour
after PAF, the animals were euthanized, the small
intestine (and in some animals, also the heart and
brain) was removed immediately, washed with ice-
cold phosphate-bu¡ered saline, and stored at
370‡C. For iNOS assay, intestinal epithelial cells
were isolated and assayed as previously described
[13]. Epithelial cells rather than whole tissue homog-
enate was used because our previous study showed
that iNOS is localized mainly in the epithelial cells
and comprises less than 10% of the total intestinal
NOS activity [9].
2.2. Assay of the NOS activity of Ca2+-dependent
(cNOS) and Ca2+-independent (iNOS) isoforms,
and the inhibition of speci¢c NOS isoform
The activity of NOS isoforms was determined by
the L-[14C]arginine conversion method as previously
published [14].
In some experiments, immunoprecipitation was
performed to remove a speci¢c NOS isoform before
the enzyme assay. 10 Wl of anti-NOS I, anti-NOS II,
or anti-NOS III antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) were mixed with 0.5 ml tissue
homogenate (protein concentration 400 Wg/ml), shak-
en at 4‡C for 2 h, and the antigen^antibody complex
was removed by incubating with protein-A agarose
beads (Santa Cruz) for 1 h followed by centrifuga-
tion. Control samples contained no antibody.
2.3. Detection of NOS isoforms by
immunoprecipitation and Western blotting
Intestinal tissue lysate was prepared as described
previously [15]. The protein concentration of the tis-
sue lysate was determined using a Sigma total pro-
tein kit (Sigma), and was adjusted to 0.5 mg/ml.
After precleaning with protein-A agarose, 1.0 ml tis-
sue lysate (0.5 mg protein) was incubated with 30 Wl
anti-NOS antibody at 4‡C with gentle shaking for
3 h, followed by incubation with 40 Wl protein-A
agarose beads for 2 h at 4‡C. The immunoprecipitate
was collected and the bound immune complex was
eluted by the addition of 200 Wl Laemmli bu¡er and
boiling. After centrifugation, 150 Wl supernatant was
loaded on a 7.5% sodium dodecyl sulfate^polyacryl-
amide gel for electrophoresis resolution. The resolved
protein was transferred to a nitrocellulose mem-
brane, and the blot was detected subsequently with
anti-NOS antibody, horseradish peroxidase-labeled
goat anti-rabbit IgG antibody, and visualized with
an ECL system from Amersham.
2.4. RNA extraction and RT^PCR
Total RNA was extracted from intestinal tissue by
homogenizing the samples in a RNA-extracting
agent, STAT-60 (TEL-TEST, Friendswood, TX), to-
gether with chloroform treatment and isopropanol
precipitation following the manufacturer’s instruc-
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tions. The total RNA was reversely transcribed (RT)
at 37‡C by using random hexamer (pdN6), and Mol-
oney murine leukemia virus (M-MLV) reverse tran-
scriptase (Gibco-BRL). An eNOS- or nNOS- se-
quence-speci¢c cDNA segment and a speci¢c
sequence of L-actin (housekeeping gene) were ampli-
¢ed by polymerase chain reaction (PCR) with Am-
pliTaq DNA polymerase and speci¢c primers £ank-
ing the corresponding gene segments. The sequence
of the primers and the PCR thermocycle pro¢les
used are as previously reported [16]. The size of the
corresponding PCR products for nNOS, eNOS, and
L-actin are 280 bp, 345 bp, and 764 bp, respectively.
The PCR products were resolved by agarose gel elec-
trophoresis and visualized by staining with SYBR
Green-1 (Molecular Probes, Eugene, OR). nNOS
transcription was analyzed by semiquantitative RT^
PCR. The £uorescence of the PCR products of
nNOS and L-actin ampli¢ed from the same reverse-
transcription reaction was analyzed using a STORM-
860 Phosphor-imager, and the nNOS/L-actin ratio
between sham-operated and PAF-treated groups
was compared.
2.5. Immuno£uorescent stains for nNOS
Five-Wm frozen tissue sections were mounted on
polylysine-coated slides and post-¢xed with ice-cold
acetone. After blocking with goat serum, the slides
were incubated with rabbit anti-nNOS antibody, fol-
lowed by incubation with biotinylated goat anti-rab-
bit IgG antibody, and £uorescein isothiocyanate
(FITC)-conjugated streptavidin.
2.6. Statistical analysis
Results are expressed as mean þ S.E.M. Compari-
son between means are made by unpaired Student’s
t-test. P6 0.05 is considered signi¢cant.
3. Results and discussion
3.1. An approximately 120 kDa nNOS is the
predominant cNOS in rat small intestine
By using the speci¢c anti-nNOS antibody R-20,
which recognizes the amino acids 1400^1419 at the
C-terminus of the rat nNOS, a band of approxi-
mately 120 kDa was precipitated from ileal tissue.
The molecular mass of this protein is less than that
of nNOS (160 kDa) from rat brain homogenate,
which was precipitated with the same antibody
(Fig. 1A). The 160 kDa nNOS is also detected, albeit
weakly, in heart tissue, but not in the rat ileum. In
contrast to nNOS, eNOS (135 kDa) is almost unde-
tectable in the small intestine (Fig. 1B), as we failed
to detect eNOS protein using a speci¢c anti-NOS III
antibody. The validity of the antibody was con¢rmed
by its strong reaction with the 135 kDa eNOS in the
heart homogenate for immunoblotting (Fig. 1B).
The PCR results support the ¢ndings of Western
blotting. RT^PCR revealed a large amount of nNOS
mRNA constitutively present in the rat ileum, where-
as little eNOS mRNA was detected (Fig. 2). In con-
trast, RT^PCR detected abundant eNOS mRNA in
heart tissue, but a relatively low level of nNOS
mRNA (Fig. 2). These ¢ndings suggest that nNOS
is the predominant cNOS in the intestine.
Immuno£uorescent stains using anti-type I NOS
antibody R-20 showed predominant localization of
the protein in the myenteric plexus and in nerve ¢-
bers within the muscle layer (Fig. 3). This is identical
Fig. 1. Immune-blotting of nNOS and eNOS in brain, heart,
and ileal tissue. (A) Western blotting of nNOS (after immuno-
precipitation) with anti-NOS I Ab R-20. A major band of ap-
proximately 120 kDa was detected in ileal tissue. The molecular
mass of nNOS from rat brain homogenate is 160 kDa. In addi-
tion, there were a few smaller and fainter bands with lower mo-
lecular mass. These may represent either sample degradation or
low-level expression of other nNOS isoform in the brain. (B)
Western blotting of eNOS (after immunoprecipitation) with
anti-NOS III Ab C-20.
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to previous reports on the localization of nNOS in
the intestine [17], suggesting that the 120 kDa protein
is nNOS.
In order to functionally verify that the 120 kDa
protein is a NOS isoform, we compared the cNOS
(Ca2-dependent) activity of the ileal homogenate
before and after the removal of type I, II, and III
NOS isoform by immunoprecipitation with the spe-
ci¢c antibody. Fig. 4 (upper) shows that immunopre-
cipitation with anti-NOS I antibody removed
80 þ 5% of the cNOS (Ca2-dependent) activity,
whereas immunoprecipitation with anti-NOS II or
anti-NOS III antibody did not signi¢cantly a¡ect
the cNOS activity. The e¡ectiveness of the latter
two antibodies to inhibit iNOS and eNOS, respec-
tively, is demonstrated by the almost 100% inhibition
of iNOS in isolated ileal epithelial cells (Fig. 4, low-
er), and approximately 70% inhibition of cNOS ac-
tivity in heart homogenate (data not shown). These
results strongly suggest that the 120 kDa protein is
responsible for most of the Ca2-dependent NOS
activity in the intestine. Based on these observations
and our previous ¢nding that more than 90% of the
total NOS activity in normal intestine is composed of
cNOS [9], we conclude that nNOS is the predomi-
nant NOS in the small intestine of normal rats. The
remaining (usually 2^5%) NOS activity, as measured
by L-[14C]arginine conversion, is Ca2-independent,
and thus is probably accounted for by iNOS in in-
testinal epithelium [9]. (Although iNOS is supposed
to be only inducible, a low level of iNOS is consti-
tutively present in normal rat intestine, mainly in the
epithelial cells [9,18].)
The nNOS mRNA and mature protein are struc-
turally diverse as a consequence of alternative pro-
moters and alternate mRNA splicing [19]. In addi-
tion to the originally cloned nNOS from a brain
cDNA library [20], several di¡erentially spliced var-
iants have been described in the rat [21]. Some of
them have a molecular mass close to 120 kDa,
such as nNOS-Q found in the skeletal muscle of mu-
tant mice [22] ; also described is a novel NOS mRNA
transcript with a N-terminal truncation in the human
testis which, when translated in CHO-K1 cells
through transfection with a construct carrying the
NOS sequence, turned out to have a molecular
mass of 125 kDa [23]. Whether the 120 kDa nNOS
we found in rat intestine is related to these nNOS
isoforms awaits its cloning. It has been suggested
that the expression of the alternative transcripts oc-
curs with a high degree of tissue speci¢city [24].
Thus, it is possible that the diversity in alternative
splicing re£ects a means of tight and speci¢c regula-
tion of nNOS in di¡erent organs.
Fig. 3. Immuno£uorescent staining of the small intestine using
anti-nNOS Ab. Frozen ileal tissue section was incubated with
R-20 (rabbit anti-rat NOS I, polyclonal, 40 Wg/ml), followed by
biotinylated goat anti-rabbit IgG Ab and FITC-conjugated
streptavidin.
Fig. 2. Gene expression of nNOS and eNOS in the ileum ana-
lyzed by semiquantitative RT^PCR. The numbers of the ther-
mocycles used for PCR ampli¢cation for nNOS, eNOS, and L-
actin were 30, 30, and 20, respectively. The sizes of the corre-
sponding PCR products are: nNOS, 280 bp; eNOS, 345 bp; L-
actin (control), 764 bp.
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It is surprising to ¢nd an almost complete absence
of eNOS in the small intestine, since it is generally
assumed (reviewed in [1]) that eNOS exerts an im-
portant protective function by maintaining adequate
blood £ow and perfusion [25^27], protecting the mu-
cosal barrier [28], and inhibiting leukocyte-endothe-
lial adhesion [6]. This assumption probably derives
from the vast amount of data from studies of iso-
lated mesenteric vessels where eNOS is abundantly
expressed [29^32]. However, the regulating mecha-
nism of the larger mesenteric vessels and their small-
er intramural branches (within the bowel wall) may
be di¡erent. This is supported by our previous study
[33] which showed that reversal of PAF-induced vas-
oconstriction of superior mesenteric artery by vaso-
dilators did not improve intestinal tissue perfusion.
Furthermore, since most of the cNOS activity in the
small intestine is accounted for by nNOS, it is pos-
sible that nNOS in the small intestine functions like
eNOS in other organs, i.e., regulating perfusion and
antagonizing leukocyte adhesion, directly or indi-
rectly. This is a plausible hypothesis, in view of the
reported localization of nNOS in the perivascular
nerve ¢bers and the adventitia of blood vessels in
many organs [34^36]. Although in this study we
did not observe nNOS in the small intestinal vessels,
other studies using more sensitive methods have re-
vealed nNOS localizing in the endothelium [37].
3.2. In vivo administration of PAF suppresses the
activity and decreases the protein content of the
120 kDa nNOS, as well as nNOS mRNA in the
intestine
To examine the regulation of the activity, protein
content and gene transcription of this 120 kDa
nNOS, we administered PAF to induce intestinal in-
jury. At the dose used (2.5 Wg/kg, i.v.), all rats devel-
op various degree of bowel injury in 1 h. As shown
in Fig. 5 (upper), 1 h after PAF injection the cNOS
activity in the intestine of PAF-treated rats is de-
creased to half of that in the sham-operated group.
This decreased enzyme activity correlates with a
marked reduction of intestinal nNOS protein con-
tent, as shown by Western blot (Fig. 5, lower), sug-
gesting that PAF down-regulates nNOS protein syn-
thesis. There is also a signi¢cant reduction in the
nNOS mRNA after PAF injection, as revealed by
RT^PCR (Fig. 5, middle), suggesting that PAF ad-
ministration also causes a decline of nNOS mRNA,
either due to a down-regulation of nNOS gene tran-
scription, or to a decrease in mRNA stability. Pre-
viously, we demonstrated [9] that the activity of
cNOS (or more accurately, nNOS) slowly increased
with time in sham-operated rats, suggesting that mild
stress (which may compromise intestinal perfusion)
such as general anesthesia and surgery, could up-reg-
ulate nNOS activity. However, when a potent in£am-
matory stimulus such as PAF is administered, the
protective nNOS is rapidly down-regulated, and in-
jury develops as a consequence [9]. The severity of
the injury is inversely correlated with the tissue
cNOS activity [9]. Further, this injury may be allevi-
Fig. 4. NOS activity after the removal of certain NOS isoforms
by speci¢c antibodies. (Upper) Ca2-dependent NOS activity in
the ileal tissue homogenate after immunoprecipitation with anti-
NOS I Ab (R-20), anti-NOS II Ab (M-19), or anti-NOS III Ab
(C-20), and agarose protein-A beads. *Inhibition level is signi¢-
cantly higher than 0 (n = 5, P6 0.05). (Lower) Ca2-independ-
ent NOS activity in isolated ileal epithelial cell homogenate
after immunoprecipitation with anti-NOS I Ab (R-20), anti-
NOS II Ab (M-19), or anti-NOS III Ab (C-20), and agarose
protein-A beads. *Inhibition level is signi¢cantly higher than 0
(n = 5, P6 0.05).
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ated if exogenous NO (from NO donor) is provided
[9]. The down-regulation of nNOS in the gastrointes-
tinal tract during in£ammation is not unique for
PAF; both LPS [38] and in£ammatory cytokines,
such as interferon-Q [39], have been known to sup-
press the transcription of nNOS in the stomach and
rectum, although their action is slower than that of
PAF. Down-regulation of intestinal nNOS may be a
common pathway to develop bowel injury in the
course of in£ammation.
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